Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(66.7%)
Phase 2
3(33.3%)
9Total
Phase 1(6)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT01190111Phase 2Terminated

Study on Interleukin-7 (CYT107) in HIV Patients

Role: lead

NCT01241643Phase 2Terminated

Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders

Role: lead

NCT01019551Phase 2Completed

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients

Role: collaborator

NCT01027065Phase 1Unknown

Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients

Role: lead

NCT01024894Phase 1Unknown

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy

Role: lead

NCT01025596Phase 1Completed

Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)

Role: lead

NCT00492440Phase 1Terminated

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

Role: lead

NCT01025297Phase 1Unknown

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone

Role: lead

NCT00477321Phase 1Completed

Safety Study of IL-7 in HIV-infected Patients (Inspire)

Role: lead

All 9 trials loaded